Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Grothey

Showing results (21-30 of 303) with videos related to

Pageof 31
Sort By:
Clinical Colorectal Cancer|April 12, 2008
Targeting the right target: epidermal growth factor receptor-directed individualized therapyAxel Grothey
Nature Clinical Practice. Oncology|January 13, 2006
Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?Axel Grothey
Seminars in Oncology|December 6, 2006
Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancerAxel Grothey
The Lancet. Oncology|November 22, 2012
VEGF inhibition beyond tumour progressionAxel Grothey
Seminars in Oncology|December 21, 2006
Is there a third-line therapy for metastatic colorectal cancer?Axel Grothey
Oncology (Williston Park, N.Y.)|September 10, 2015
Maintenance therapy in the treatment of metastatic colorectal cancer. Axel Grothey, MDAxel Grothey
Clinical Advances in Hematology & Oncology : H&O|May 10, 2018
Highlights in metastatic colorectal cancer from the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium: commentaryAxel Grothey
Oncology|March 31, 2011
Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancerAxel Grothey
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
EGFR antibodies in colorectal cancer: where do they belong?Axel Grothey
Nature Clinical Practice. Oncology|October 30, 2008
A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancerAxel Grothey
Pageof 31

Showing results (21-30 of 303) with videos related to

Sort By:
Pageof 31
Clinical Colorectal Cancer|April 12, 2008
Targeting the right target: epidermal growth factor receptor-directed individualized therapyAxel Grothey
Nature Clinical Practice. Oncology|January 13, 2006
Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?Axel Grothey
Seminars in Oncology|December 6, 2006
Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancerAxel Grothey
The Lancet. Oncology|November 22, 2012
VEGF inhibition beyond tumour progressionAxel Grothey
Seminars in Oncology|December 21, 2006
Is there a third-line therapy for metastatic colorectal cancer?Axel Grothey
Oncology (Williston Park, N.Y.)|September 10, 2015
Maintenance therapy in the treatment of metastatic colorectal cancer. Axel Grothey, MDAxel Grothey
Clinical Advances in Hematology & Oncology : H&O|May 10, 2018
Highlights in metastatic colorectal cancer from the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium: commentaryAxel Grothey
Oncology|March 31, 2011
Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancerAxel Grothey
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
EGFR antibodies in colorectal cancer: where do they belong?Axel Grothey
Nature Clinical Practice. Oncology|October 30, 2008
A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancerAxel Grothey
Pageof 31